Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: For precision medicine, exploration and monitoring of molecular biomarkers are essential. However, in advanced gas tric cancer (GC) with visceral lesions, an invasive procedure cannot be performed repeatedly for the follow-up of molecular bio markers. Materials and Methods: To verify the clinical implication of serial liquid biopsies targeting circulating tumor DNA (ctDNA) on treatment response, we conducted targeted deep sequencing for serially collected ctDNA of 15 HER2-positive metastatic GC pa tients treated with anti-PD-1 inhibitor in combination with standard systemic treatment. Results: In the baseline ctDNAs, 14 patients (93%) harbored more than one genetic alteration. A number of mutations in well known cancer-related genes, such as KRAS and PIK3CA, were identified. Copy number alterations were identified in eight GCs (53.3%), and amplification of the ERBB2 gene (6/15, 40.0%) was the most recurrent. When we calculated the mean variant allele frequency (VAF) of mutations in each ctDNA as the molecular tumor burden index (mTBI), the mTBI trend was largely consistent with the VAF profiles in both responder and non-responder groups. Notably, in the longitudinal analysis of ctDNA, mTBI provided 2–42 weeks (mean 13.4 weeks) lead time in the detection of disease progression compared to conventional follow-up with CT im aging. Conclusion: Our data indicate that the serial genetic alteration profiling of ctDNA is feasible to predict treatment response in HER2-positive GC patients in a minimally invasive manner. Practically, ctDNA profiles are useful not only for the molecular diag nosis of GC but also for the selection of GC patients with poor prognosis for systemic treatment (ClinicalTrials.gov identifier: NCT02901301).
Abstract
Purpose: For precision medicine, exploration and monitoring of molecular biomarkers are essential. However, in advanced gas tric cancer (GC) with visceral lesions, an invasive procedure cannot be performed repeatedly for the follow-up of molecular bio markers. Materials and Methods: To verify the clinical implication of serial liquid biopsies targeting circulating tumor DNA (ctDNA) on treatment response, we conducted targeted deep sequencing for serially collected ctDNA of 15 HER2-positive metastatic GC pa tients treated with anti-PD-1 inhibitor in combination with standard systemic treatment. Results: In the baseline ctDNAs, 14 patients (93%) harbored more than one genetic alteration. A number of mutations in well known cancer-related genes, such as KRAS and PIK3CA, were identified. Copy number alterations were identified in eight GCs (53.3%), and amplification of the ERBB2 gene (6/15, 40.0%) was the most recurrent. When we calculated the mean variant allele frequency (VAF) of mutations in each ctDNA as the molecular tumor burden index (mTBI), the mTBI trend was largely consistent with the VAF profiles in both responder and non-responder groups. Notably, in the longitudinal analysis of ctDNA, mTBI provided 2–42 weeks (mean 13.4 weeks) lead time in the detection of disease progression compared to conventional follow-up with CT im aging. Conclusion: Our data indicate that the serial genetic alteration profiling of ctDNA is feasible to predict treatment response in HER2-positive GC patients in a minimally invasive manner. Practically, ctDNA profiles are useful not only for the molecular diag nosis of GC but also for the selection of GC patients with poor prognosis for systemic treatment (ClinicalTrials.gov identifier: NCT02901301).
참고문헌 (35)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018", Cancer Research and Treatment, 53(2), pp.301~315 (2021), 대한암학회[DOI]
- Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
- The Cancer Genome Atlas Research Network, "Integrated genomic characterization of oesophageal carcinoma", Nature, 541, pp.169~175 (2017)
- Zang ZJ, "Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes", Nat Genet, 44, pp.570~574 (2012)
- Wang K, "Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer", Nat Genet, 46, pp.573~582 (2014)
- Jung SH, "Clonal structures of regionally synchronous gastric adenomas and carcinomas", Clin Cancer Res, 24, pp.4715~4725 (2018)
- Swanton C, "Intratumor heterogeneity : evolution through space and time", Cancer Res, 72, pp.4875~4882 (2012)
- Diaz LA Jr, "Liquid biopsies : genotyping circulating tumor DNA", J Clin Oncol, 32, pp.579~586 (2014)
- Schwaederle M, "Use of liquid biopsies in clinical oncology : pilot experience in 168 patients", Clin Cancer Res, 22, pp.5497~5505 (2016)
- Kim ST, "Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer", Nat Med, 24, pp.1449~1458 (2018)
- Normando SRC, "Circulating free plasma tumor DNA in patients with advanced gastric cancer receiving systemic chemotherapy", BMC Clin Pathol, 18, pp.12~ (2018)
- Rothwell DG, "Utility of ctDNA to support patient selection for early phase clinical trials : the TARGET study", Nat Med, 25, pp.738~743 (2019)
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
- Janjigian YY, "First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer : an open-label, single-arm, phase 2 trial", Lancet Oncol, 21, pp.821~831 (2020)
- Rha SY, "A multiinstitutional phase Ib", II trial of first-line triplet regimen(pembrolizumab, trastuzumab, chemotherapy)for HER2-positive advanced gastric and gastroesophageal junction cancer(PANTHERA trial) : molecular profiling and clinical update, 2021, pp.39, 218~
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Bartley AN, "HER2 testing and clinical decision making in gastroesophageal adenocarcinoma : guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology", J Clin Oncol, 35, pp.446~464 (2017)
- Kim HS, "Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer", Oncotarget, 8, pp.38389~38398 (2017)
- Wang K, "ANNOVAR : functional annotation of genetic variants from high-throughput sequencing data", Nucleic Acids Res, 38, pp.e164~ (2010)
- Wang Y, "Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer", EBioMedicine, 43, pp.261~269 (2019)
- Burrell RA, "Tumour heterogeneity and the evolution of polyclonal drug resistance", Mol Oncol, 8, pp.1095~1111 (2014)
- Yamamoto H, "Non-invasive early molecular detection of gastric cancers", Cancers(Basel), 12, pp.2880~ (2020)
- Wang DS, "Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer", Gut, 68, pp.1152~1161 (2019)
- Sakai H, "HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine(T-DM1)in patients with HER2-positive metastatic breast cancer", Breast Cancer, 25, pp.605~613 (2018)
- Niu D, "Evaluation of next generation sequencing for detecting HER2 copy number in breast and gastric cancers", Pathol Oncol Res, 26, pp.2577~2585 (2020)
- Kim SB, "Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS", Lancet Oncol, 18, pp.e638~ (2017)
- Wang F, "Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib", II clinical trial NCT02915432, 2019, pp.30, 1479~1486
- Rizvi NA, "Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", Science, 348, pp.124~128 (2015)
- Van Allen EM, "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma", Science, 350, pp.207~211 (2015)
- Fancello L, "Tumor mutational burden quantification from targeted gene panels : major advancements and challenges", J Immunother Cancer, 7, pp.183~ (2019)
- Wu HX, "Designing gene panels for tumor mutational burden estimation : the need to shift from ‘correlation’ to ‘accuracy’", J Immunother Cancer, 7, pp.206~ (2019)
- Onidani K, "Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA", Cancer Sci, 110, pp.2590~2599 (2019)
- Chabon JJ, "Integrating genomic features for non-invasive early lung cancer detection", Nature, 580, pp.245~251 (2020)
- Niroula A, "Distinction of lymphoid and myeloid clonal hematopoiesis", Nat Med, 27, pp.1921~1927 (2021)